According to the preclinical data, ISM1745 demonstrated robust in vivo efficacy at a low dosage in multiple animal models, with promising potency as monotherapy and broad potential in combination with chemotherapies, targeted agents, and immunotherapies. (IMAGE)

InSilico Medicine

According to the preclinical data, ISM1745 demonstrated robust in vivo efficacy at a low dosage in multiple animal models, with promising potency as monotherapy and broad potential in combination with chemotherapies, targeted agents, and immunotherapies.

Caption

The combination potential with MAT2A inhibitor has been validated in both in vitro and in vivo tests. 

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.